ICU study explores cutting back on antifungals for vulnerable patients
NCT ID NCT03774316
First seen Jan 04, 2026 · Last updated May 15, 2026 · Updated 18 times
Summary
This study looked at whether it is safe to reduce or stop antifungal drugs early in immunocompromised patients in the ICU who are being treated for a suspected candida infection. Researchers tracked 275 patients across 14 ICUs to see how often treatment was reduced and what factors made that possible. The goal was to understand if de-escalation can lower side effects, drug resistance, and costs without harming patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CRITICAL ILLNESS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU Lille
Lille, 59000, France
Conditions
Explore the condition pages connected to this study.